Media Release

Basel, 11 May 2017

Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

- 20 Roche medicines are included in more than 190 abstracts during ASCO 2017
- New pivotal results for Perjeta (pertuzumab) and Alecensa (alectinib) improve upon standards of care
- Early results from Roche’s broad cancer development programme preview next generation of cancer immunotherapy including Roche’s first T-cell bispecific antibody

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 2 June to 6 June in Chicago, United States. More than 190 abstracts have been accepted, including two “late breakers” and 24 oral presentations.

“We are making significant advances with personalised medicines and cancer immunotherapies,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “With continued research and collaborations, we are striving to develop medicines and combinations, incorporate sophisticated diagnostics and integrate big data in our effort to get closer to the goal of curing cancer.”

Key highlights from the Roche oncology portfolio include new results from the APHINITY study in early breast cancer and the ALEX study in lung cancer. Both of these studies will be highlighted as part of ASCO’s official press program on Monday 5 June. APHINITY is a randomised phase III study, investigating Perjeta® plus Herceptin® (trastuzumab) and chemotherapy as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer.
The APHINITY study was conducted in collaboration with the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS). ALEX is a randomised, multicentre, open-label phase III study that compared Alecensa® and crizotinib in people with previously untreated ALK-positive non-small cell lung cancer (NSCLC).

There has been great progress in the area of cancer immunotherapy in recent years and Roche continues to investigate novel ways to harness the immune system in the fight against cancer as part of its vision to bring the next generation of cancer immunotherapies to patients. With more than 20 investigational cancer immunotherapies in development and 12 in clinical trials, Roche will be presenting early results on its first T-cell bispecific antibody (CEA-CD3 TCB: RG7802; RO6958688) for the treatment of CEA-positive cancers, including metastatic colorectal cancer (mCRC). These data have been generated from two ongoing dose-escalation phase I studies in which CEA-CD3 TCB is used alone or in combination with TECENTRIQ® (atezolizumab).

Further information on Roche’s contribution to the ASCO 2017 scientific program, as well as Roche’s wider progress in cancer care, will be featured during the Roche media briefing from 09:00–10:45 CDT on Friday, 2 June at the Chicago Marriott Hotel Downtown Magnificent Mile. This event, independently organised by Roche, is open to journalists from outside the United States who have registered as media with the ASCO 2017 Annual Meeting. To register, please follow http://roche.cvent.com/d/15qz2b.

Follow Roche on Twitter via @Roche and keep up to date with ASCO 2017 Annual Meeting news and updates by using the hashtag #ASCO17. For more information on Roche’s approach to cancer, visit the Roche Oncology Hub at Roche.com.
## Overview of key presentations featuring Roche medicines at ASCO 2017

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Abstract title</th>
<th>Abstract number</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Perjeta</strong> <em>(pertuzumab)</em></td>
<td>*<em>APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)</em></td>
<td>Abstract LBA500 (oral) Monday, 5 June 09:45 - 12:45 CDT</td>
</tr>
<tr>
<td><strong>Alecensa</strong> <em>(alectinib)</em></td>
<td>Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study</td>
<td>Abstract LBA9008 (oral) Tuesday, 6 June 09:45 - 12:45 CDT</td>
</tr>
<tr>
<td><strong>CEA-CD3 TCB</strong> <em>(RG7802)</em></td>
<td>Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC)</td>
<td>Abstract 3002 (oral) Monday, 5 June 13:15 - 16:15 CDT</td>
</tr>
<tr>
<td><strong>ipatasertib</strong> <em>(investigational use)</em></td>
<td>LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC)</td>
<td>Abstract 1009 (poster) Sunday, 4 June 16:45 – 18.00 CDT</td>
</tr>
<tr>
<td><strong>TECENTRIQ</strong> <em>(atezolizumab)</em></td>
<td>IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).</td>
<td>Abstract 4505 (oral) Monday, 5 June 08:00 – 10:00 CDT</td>
</tr>
<tr>
<td><strong>TECENTRIQ</strong> <em>(atezolizumab)</em></td>
<td>Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.</td>
<td>Abstract 9092 (poster) Saturday, 3 June 08:00 – 11:30 CDT</td>
</tr>
<tr>
<td><strong>TECENTRIQ</strong> <em>(atezolizumab)</em></td>
<td>Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC).</td>
<td>Abstract 5585 (poster) Saturday, 3 June 13:15 – 16:45 CDT</td>
</tr>
<tr>
<td><strong>TECENTRIQ</strong> <em>(atezolizumab)</em></td>
<td>Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.</td>
<td>Abstract 9001 (oral) Tuesday, 6 June 09:45 – 12:45 CDT</td>
</tr>
<tr>
<td><strong>TECENTRIQ / IDO1</strong> <em>(atezolizumab / GDC-0919)</em></td>
<td>A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.</td>
<td>Abstract 105 (oral) Sunday, 4 June 09:45 – 11:15 CDT</td>
</tr>
</tbody>
</table>
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche-global.com
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Simone Oeschger
- Anja von Treskow